Killeen Sarah Louise, Byrne David F, Geraghty Aisling A, Kilbane Mark T, Twomey Patrick J, McKenna Malachi J, Yelverton Cara A, Saldova Radka, Van Sinderen Douwe, Cotter Paul D, Murphy Eileen F, McAuliffe Fionnuala M
UCD Perinatal Research Centre, School of Medicine, University College Dublin, National Maternity Hospital, Dublin, Ireland,
UCD Perinatal Research Centre, School of Medicine, University College Dublin, National Maternity Hospital, Dublin, Ireland.
Ann Nutr Metab. 2022;78(3):177-182. doi: 10.1159/000522564. Epub 2022 Mar 18.
Metabolic or inflammatory markers may predict adverse outcomes in women with obesity. We sought to describe metabolic-obesity phenotypes of women using novel staging tools and investigate relationships with inflammation.
In a cross-sectional study, we collected fasting blood samples from sixty-four females with body mass index (BMI) ≥28 kg/m2. Participants were classified as metabolically healthy or metabolically unhealthy obesity (MUO) using the cardiometabolic disease staging system (CMDS) and Edmonton obesity staging system (EOSS). Data were analyzed using independent sample t tests, Pearson's correlations, and multiple logistic regression.
Mean (SD) age was 40.2 (9.3) years with median (IQR) BMI 31.8 (30.3-35.7) kg/m2. The prevalence of MUO was 46.9% and 81.3% using CMDS and EOSS criteria, respectively. Women with raised CMDS scores had higher C3 (1.34 [0.20] vs. 1.18 [0.15], p = 0.001) and C-reactive protein (CRP) (2.89 [1.31-7.61] vs. 1.39 [0.74-3.60], p = 0.034). C3 correlated with insulin (r = 0.52), hemoglobin A1c (r = 0.37), and C-peptide (r = 0.58), all p < 0.05. C3 above the median (>1.23 g/L) increased odds of raised CMDS score, when controlled for age, BMI, ethnicity, and smoking (OR = 6.56, 95% CI: 1.63, 26.47, p = 0.008).
The prevalence of MUO was lower using CMDS than EOSS. C3 and CRP may be useful clinical biomarkers of risk or treatment targets in women with obesity.
代谢或炎症标志物可能预测肥胖女性的不良结局。我们试图使用新型分期工具描述女性的代谢性肥胖表型，并研究其与炎症的关系。
在一项横断面研究中，我们收集了64名体重指数（BMI）≥28kg/m²的女性的空腹血样。使用心脏代谢疾病分期系统（CMDS）和埃德蒙顿肥胖分期系统（EOSS）将参与者分类为代谢健康或代谢不健康肥胖（MUO）。使用独立样本t检验、Pearson相关性分析和多元逻辑回归分析数据。
平均（标准差）年龄为40.2（9.3）岁，BMI中位数（四分位间距）为31.8（30.3 - 35.7）kg/m²。使用CMDS和EOSS标准时，MUO的患病率分别为46.9%和81.3%。CMDS评分升高的女性C3水平更高（1.34[0.20]对1.18[0.15]，p = 0.001），C反应蛋白（CRP）水平也更高（2.89[1.31 - 7.61]对1.39[0.74 - 3.60]，p = 0.034）。C3与胰岛素（r = 0.52）、糖化血红蛋白（r = 0.37）和C肽（r = 0.58）相关，均p < 0.05。在控制年龄、BMI、种族和吸烟因素后，C3高于中位数（>1.23g/L）会增加CMDS评分升高可能性（比值比 = 6.56，95%置信区间：1.63，26.47，p = 0.008）。
使用CMDS时MUO的患病率低于EOSS。C3和CRP可能是肥胖女性风险或治疗靶点的有用临床生物标志物。
